Securities code: Sirio Pharma Co.Ltd(300791) securities abbreviation: Sirio Pharma Co.Ltd(300791) announcement Code: 2022019 securities code: 123113 securities abbreviation: xianle convertible bonds
Announcement on applying for comprehensive bank credit in 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Sirio Pharma Co.Ltd(300791) (hereinafter referred to as “the company”) held the 7th Meeting of the 3rd board of directors on April 8, 2022, which deliberated and adopted the proposal on the company’s application for comprehensive bank credit in 2022, which needs to be submitted to the general meeting of shareholders of the company for deliberation. The details are hereby announced as follows:
1、 Basic information
In order to prepare for the possible capital needs of the company’s operation, the company plans to provide guarantee for the company to obtain the credit line with its own land, real estate, equipment and funds. The company applies to cooperative banks for a comprehensive credit line of no more than 1.2 billion yuan.
The company’s wholly-owned subsidiary Sirio Pharma Co.Ltd(300791) Technology (Anhui) Co., Ltd. (hereinafter referred to as “Anhui xianle”) provides guarantee for financing with its own land, real estate and equipment, and applies for a comprehensive credit line of no more than 200 million yuan from China Minsheng Banking Corp.Ltd(600016) Shantou branch.
The above credit shall be subject to the credit line actually approved by relevant banks. The above credit line is not equal to the actual financing amount of the company and Anhui xianle. The actual financing amount shall be within the credit line, and the actual financing amount between the bank and the company and Anhui xianle shall prevail.
The validity period of the above credit matters is one year from the date of deliberation and approval of the 2021 annual general meeting of shareholders. The above credit line can be recycled within the validity period, and the management of the company is authorized to implement specific matters.
2、 Documents for future reference
1. Resolution of the 7th Meeting of the 3rd board of directors.
It is hereby announced.
Sirio Pharma Co.Ltd(300791) board of directors
April 12, 2002
